Form D · Biotechnology
LUMICELL, INC.
Newton, MA · CIK 0001521898
Offering snapshot reported May 6, 2025 · SEC filing
- Reported sold
- $198M Indefinite offering
- Investors reported
- 64 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 22, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 6, 2025 | Initial | $198,128,718 | No comparison | 64 | SEC filing |
| Jul 25, 2024 | Initial | $2,730,612 | No comparison | 11 | SEC filing |
| Mar 8, 2024 | Initial | $2,275,000 | No comparison | 6 | SEC filing |
| Jul 26, 2023 | Initial | $75,843,150 | No comparison | 47 | SEC filing |
| Dec 20, 2018 | Initial | $20,365,906 | No comparison | 25 | SEC filing |
| Oct 18, 2017 | Initial | $20,705,024 | No comparison | 24 | SEC filing |
| May 4, 2016 | Initial | $6,769,997 | No comparison | 10 | SEC filing |
| Feb 25, 2014 | Amendment | $1,563,572 | $549,990vs Jan 3, 2014 | 7 | SEC filing |
| Jan 3, 2014 | Initial | $1,013,582 | No comparison | 5 | SEC filing |
| Jun 1, 2011 | Initial | $2,708,236 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $396K (estimated)
- Finders' fees
- $0
- Form D file number
- 021-545378
The offering includes securities to be acquired upon the exchange of other securities and the exchange value is not currently known or knowable. The amount sold includes a good faith valuation of the non-cash consideration received.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Network 1 Financial Securities Inc. | 13577 |
Source: Form D, filed May 6, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| James Alecxih | Director |
| Moungi Bawendi | Director |
| Elon Boms | Director |
| Jorge Ferrer | Executive |
| Cosimo Fiorenza | Director |
| David Furneaux | Director |
| Carlos Gonzalez | Director |
| Howard Hechler | Director, Executive |
| Kevin Hershberger | Director, Executive |
| William D. Johnson | Executive |
| Kevin Krenitsky | Director |
| W. David Lee | Director |
| Kelly Londy | Director, Executive |
| Mike Ruettgers | Director |
| Michael Ruettgers | Director |
| James Schuermann | Director |
| Ralph Weissleder | Director |
| Andrey J. Zarur | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
275 Washington Street Ste. 200
Newton, MA, 02458
Newton, MA, 02458